Immunomodulatory drugs and their therapeutic effect in hematological malignancies through cereblon

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023736%3A_____%2F17%3A00011762" target="_blank" >RIV/00023736:_____/17:00011762 - isvavai.cz</a>
Result on the web
<a href="https://oatext.com/pdf/HMO-2-129.pdf" target="_blank" >https://oatext.com/pdf/HMO-2-129.pdf</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.15761/HMO.1000129" target="_blank" >10.15761/HMO.1000129</a>

Result language
angličtina
Original language name
Immunomodulatory drugs and their therapeutic effect in hematological malignancies through cereblon
Original language description
Immunomodulatory drugs (IMiDs), today also known as cereblon (CRBN) binding drugs, are therapeutically important anti-cancer and anti-inflammatory drugs. IMiDs are analogs of their prototype compound thalidomide. IMiDs have immune-modulation, anti-angiogenic, anti-inflammatory and anti-proliferative effects. CRBN is a component and substrate receptor of the Cullin 4 Ring E3 Ubiquitin Protein Ligase complex (CRL4). CRL4 consists of Cullin 4, RING finger protein (Roc1), and DNA damage binding protein 1 (DDB1). CRBN binds to its substrate proteins and it leads to ubiquitination of these substrates by the CRL4. CRBN is also involved in IMiDs-mediated T-cell co-stimulation and cytokine production. CRBN is a primary target of thalidomide teratogenicity. The binding of IMiDs to CRBN is associated with cytotoxicity of IMiDs and is used to treat multiple myeloma (MM), myelodysplastic syndromes (MDS), lymphomas and chronic lymphocytic leukemia.
Czech name
—
Czech description
—

Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2017
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)